1Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol, 2004, 172 (4 Pt 1 ) : 1297-1301.
2Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412 (6849) : 822-826.
3Li J, White N, Zhang Z, et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol, 2004, 171 (5) : 1782-1787.
4Paul B, Dhir R, Landsittel D, et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res, 2005, 65(10): 4097-4100.
5Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med, 2004, 350(22) : 2239-2246.
6Partin AM, Getzenberg RH, CarMichael MJ, et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res, 1993, 53 (4) : 744-746.
7Uetsuki H, Tsunemori H, Taoka R, et al. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol, 2005, 174(2) : 514-518.
8Leman ES, Cannon GW, Trock B J, et al. EPCA-2: A highly specific serum marker for prostate cancer. Urology, 2007, 69 (4) : 714-720.
9Nickerson JA. Nuclear dreams: The malignant alteration of nuclear architecture. J Cell Biochem, 1998, 70(2) : 172-180.
10Getzenberg RH. Nuclear matrix and the regulation of gene expression: Tissue specificity. J Cell Biochem, 1994, 55( 1 ) : 22- 31.
